NCCN Request for Proposals (RFP): Phase I/II Clinical Trials and Pre-Clinical Trials of Enzalutamide for Selected Cancers
The National Comprehensive Cancer Network® (NCCN®) has received a research grant from Astellas Pharma, Inc. and Medivation, Inc. to support NCCN investigator initiated clinical and pre-clinical studies of enzalutamide in the treatment of selected solid tumors. The overall aim of this RFP is to develop innovative studies of enzalutamide in prostate, breast, hepatocellular, bladder, and gynecologic cancers. Collaborative studies between NCCN Member Institutions are encouraged.
LOIs are due by 5 pm EDT on Monday, July 28, 2014. See the attached Request for Proposals (RFP), which clearly outlines the scope and the process for the submission of Letters of Intent (LOIs).
- Enzalutamide_RFP_30JUN14.pdf209 K